SNY

AI Memo

Sanofi

As of 2026-08-05/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-05 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Q2 growth and 2026 guidance upgrade • 2026-07-30

Base target: $49 / p=50% prob

Biggest risk

Forward visibility remains limited despite the guidance upgrade. R&D expenses rose 17.9%, vaccines declined 4.7% on a difficult comparison, IFRS EPS fell sharply, and pipeline prioritization included discontinuations. Analyst revision and target-change data after the print are unavailable.

Invalidation

Break below $37 or thesis failure.

What would change my mind?

Strong Q2 execution, rapid Dupixent growth, launch momentum, free-cash-flow improvement, and upgraded 2026 guidance support a constructive medium-term setup. The supplied median analyst target of $50.60 implies approximately 18.6% upside from the $42.68 anchor price.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-05

Base target

$49

p=50%

Bull target

$56

p=25%

Bear target

$37

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Second-half normalization and pipeline reset digestion
Pipeline and regulatory milestone execution
Commercial execution from Dupixent and newer launches

BearKey bullets

Clinical, regulatory, safety, manufacturing, competitive, and pricing risks across the biopharma portfolio.
Continued reliance on Dupixent and successful execution of newer pharmaceutical launches.
Pipeline productivity risk following amlitelimab discontinuation in atopic dermatitis and discontinuation of itepekimab and balinatunfib programs.

WatchKey bullets

Q2 growth and 2026 guidance upgrade

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $49 (p=50%)

Target spread vs base: +14% / -24%

Scenario probabilities

Bull Target: $56 (p=25%)Base Target: $49 (p=50%)Bear Target: $37 (p=25%)

Commentary

Primary-company news tone is positive after strong Q2 growth, upgraded guidance, and the MenQuadfi approval, but the evidence packet lacks social coverage, options data, short interest, employee sentiment, and verified post-print analyst revisions. The $42.68 August 4 anchor indicates that the positive earnings narrative is not fully reflected versus the supplied $50.60 median target, but the high uncertainty score and pipeline reset argue for monitoring rather than aggressive conviction.

As of 2026-08-05 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Second-half normalization and pipeline reset digestion
Pipeline and regulatory milestone execution
Commercial execution from Dupixent and newer launches

Scenarios

Bull Target (Scenario probability)

$56 / p=25% prob

Base Target (Scenario probability)

$49 / p=50% prob

Bear Target (Scenario probability)

$37 / p=25% prob

Analysis 2026-08-05 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.62

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-30
Q2 growth and 2026 guidance upgrade
Sanofi reported Q2 sales growth of 17.8% at constant exchange rates, Dupixent growth of 37.6%, business EPS growth of 33.3%, and upgraded 2026 sales guidance to around 10% growth with business EPS growing slightly faster [#PR-EARNINGS-2026-07-30].
Prob 100.00% • Move 5.00% • Priced-in 90.00%
EVENT2026-08-04
MenQuadfi EU infant indication approval
The European Commission approved MenQuadfi for infants from six weeks of age, expanding the addressable pediatric indication in the EU [#PR-2026-08-04].
Prob 100.00% • Move 1.50% • Priced-in 85.00%

Short-term Catalysts

Next few weeks

Second-half normalization and pipeline reset digestion
2026-09-30
Sanofi expects growth to normalize in the second half and has discontinued amlitelimab development in atopic dermatitis plus two other clinical programs, creating execution and sentiment risk [#PR-EARNINGS-2026-07-30] [#PR-2026-07-24].
Prob 75% • Move -4% • Priced-in 60%

Long-term Catalysts

Months to a year

Pipeline and regulatory milestone execution
2026-12-31
The company reported seven regulatory approvals and two positive phase 3 readouts; a phase 2 amlitelimab celiac-disease readout is expected in the second half of 2026 [#PR-EARNINGS-2026-07-30] [#PR-2026-07-24].
Prob 50% • Move 8% • Priced-in 35%
Commercial execution from Dupixent and newer launches
2030-12-31
Management targets approximately €25 billion of Dupixent sales and approximately €10 billion from pharmaceutical launches in 2030, but delivery depends on continued uptake and execution [#PR-EARNINGS-2026-07-30].
Prob 55% • Move 15% • Priced-in 45%

Risks

Clinical, regulatory, safety, manufacturing, competitive, and pricing risks across the biopharma portfolio.
Continued reliance on Dupixent and successful execution of newer pharmaceutical launches.
Pipeline productivity risk following amlitelimab discontinuation in atopic dermatitis and discontinuation of itepekimab and balinatunfib programs.
Post-print analyst estimate revisions, target changes, and reliable attribution of the market reaction are unavailable.
Second-half growth normalization could pressure expectations after the Q2 guidance upgrade.

Peers

Symbol	Summary
REGN	Closest same-sector operating comparison in the supplied peer set, but Sanofi-specific portfolio mix and guidance should remain the primary reference.
VRTX	Large-cap biopharma peer with relevant innovation and pipeline characteristics, though its product and disease-area mix is materially different.
AMGN	Large diversified biopharma comparator; useful for scale and defensive-sector context but not a tight operating comp.
BMY	Large pharmaceutical peer with comparable sector exposure, but portfolio, patent, and pipeline profiles are loose matches.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-05

Loading AI feed…

Symbol

Summary

REGN

Closest same-sector operating comparison in the supplied peer set, but Sanofi-specific portfolio mix and guidance should remain the primary reference.

VRTX

Large-cap biopharma peer with relevant innovation and pipeline characteristics, though its product and disease-area mix is materially different.

AMGN

Large diversified biopharma comparator; useful for scale and defensive-sector context but not a tight operating comp.

BMY

Large pharmaceutical peer with comparable sector exposure, but portfolio, patent, and pipeline profiles are loose matches.